136187-43-4

Upstream product

• 137789-54-9 diethyl {2-[(4S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-2-oxoethyl}phosphonate 
• 2043-61-0 cyclohexanecarbaldehyde 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 39098-75-4 3-cyclohexylpropionyl chloride 

Downstream Products

• 1013088-41-9 (2'S,4S)-3-(2-fluoro-3-cyclohexyl-1-oxopropyl)-4-phenylmethyl-2-oxazolidinone 
• 1176225-38-9 (S)-4-benzyl-3-((S)-2-(cyclohexylmethyl)pent-4-enoyl)oxazolidin-2-one 

Relevant academic research and scientific papers

Regio-selective reduction of the C-C double bonds in α,β- unsaturated acyl 4-substituted oxazolidin-2-ones and oxazolidine-2-thiones

Selective saturation of the conjugated C-C double bonds in the title compounds was examined in a systematic way for the first time. Many established protocols effective for similar reduction of α,β-unsaturated ketones and esters in the literature were found to be inapplicable in the present context. The most satisfactory results were finally obtained using the DIBAL-H/MeLi/CuI/HMPA/THF conditions.

Renin Inhibitors

Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

Enantioselective synthesis of α-fluorinated β2-amino acids

A methodology for the enantioselective synthesis of α-fluorinated β2-amino acids has been developed from readily available carboxylic acids 3. Conversion to the Evan's oxazolidinone followed by enantioselective fluorination and alkylation gave 7 in high diastereomeric excess (>95%). Subsequent removal of the oxazolidinone and amination at the Bn-protected hydroxyl center gave optically active α-fluorinated β2-amino acids.

Renin inhibitors having all retro-inverted peptide bonds

Renin-inhibiting peptides of the formula STR1 in which X represents a group of the formula STR2 represents hydroxyl, alkoxy having up to 8 carbon atoms, benzyloxy or a group of the formula --NR4 R5, A, B, D and E are identical or different and in each case represent a direct bond, represent a radical of the formula STR3 in which Q1 denotes oxygen, sulphur or the methylene group represent a grouping of the formula STR4 m represents a number 0, 1 or 2, and L represents a group of the formula --CH2 NR2 R3 and physiologically acceptable salts thereof.